Next Article in Journal
Avian Antimicrobial Host Defense Peptides: From Biology to Therapeutic Applications
Next Article in Special Issue
Amino Acid Prodrugs: An Approach to Improve the Absorption of HIV-1 Protease Inhibitor, Lopinavir
Previous Article in Journal
Mitochondrial FAD-linked Glycerol-3-phosphate Dehydrogenase: A Target for Cancer Therapeutics
Previous Article in Special Issue
The Dipeptide Monoester Prodrugs of Floxuridine and Gemcitabine—Feasibility of Orally Administrable Nucleoside Analogs
Pharmaceuticals 2014, 7(2), 207-219; doi:10.3390/ph7020207
Article

Design of Prodrugs to Enhance Colonic Absorption by Increasing Lipophilicity and Blocking Ionization

1,†,* , 2,†,‡
, 3
, 4
, 1
, 1
, 5
, 6
, 4
, 4
, 3
, 3
, 2
, 2
, 4
, 7
, 8
 and 1
Received: 20 January 2014; in revised form: 8 February 2014 / Accepted: 12 February 2014 / Published: 24 February 2014
(This article belongs to the Special Issue Prodrugs)
View Full-Text   |   Download PDF [128 KB, uploaded 24 February 2014]   |   Browse Figure
Abstract: Prodrugs are chemistry-enabled drug delivery modifications of active molecules designed to enhance their pharmacokinetic, pharmacodynamic and/or biopharmaceutical properties. Ideally, prodrugs are efficiently converted in vivo, through chemical or enzymatic transformations, to the active parent molecule. The goal of this work is to enhance the colonic absorption of a drug molecule with a short half-life via a prodrug approach to deliver sustained plasma exposure and enable once daily (QD) dosing. The compound has poor absorption in the colon and by the addition of a promoiety to block the ionization of the molecule as well as increase lipophilicity, the relative colonic absorption increased from 9% to 40% in the retrograde dog colonic model. A combination of acceptable solubility and stability in the gastrointestinal tract (GI) as well as permeability was used to select suitable prodrugs to optimize colonic absorption.
Keywords: prodrugs; colonic absorption; dog colonic studies; enabling QD dosing; chemistry-enabled drug delivery; enhancing lipophilicity prodrugs; colonic absorption; dog colonic studies; enabling QD dosing; chemistry-enabled drug delivery; enhancing lipophilicity
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Nofsinger, R.; Clas, S.-D.; Sanchez, R.I.; Walji, A.; Manser, K.; Nissley, B.; Balsells, J.; Nair, A.; Dang, Q.; Bennett, D.J.; Hafey, M.; Wang, J.; Higgins, J.; Templeton, A.; Coleman, P.; Grobler, J.; Smith, R.; Wu, Y. Design of Prodrugs to Enhance Colonic Absorption by Increasing Lipophilicity and Blocking Ionization. Pharmaceuticals 2014, 7, 207-219.

AMA Style

Nofsinger R, Clas S-D, Sanchez RI, Walji A, Manser K, Nissley B, Balsells J, Nair A, Dang Q, Bennett DJ, Hafey M, Wang J, Higgins J, Templeton A, Coleman P, Grobler J, Smith R, Wu Y. Design of Prodrugs to Enhance Colonic Absorption by Increasing Lipophilicity and Blocking Ionization. Pharmaceuticals. 2014; 7(2):207-219.

Chicago/Turabian Style

Nofsinger, Rebecca; Clas, Sophie-Dorothee; Sanchez, Rosa I.; Walji, Abbas; Manser, Kimberly; Nissley, Becky; Balsells, Jaume; Nair, Amrithraj; Dang, Qun; Bennett, David J.; Hafey, Michael; Wang, Junying; Higgins, John; Templeton, Allen; Coleman, Paul; Grobler, Jay; Smith, Ronald; Wu, Yunhui. 2014. "Design of Prodrugs to Enhance Colonic Absorption by Increasing Lipophilicity and Blocking Ionization." Pharmaceuticals 7, no. 2: 207-219.


Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert